First Patient Dosed in Phase 2b/3 Study of TD-1473 for Ulcerative Colitis

First Patient Dosed in Phase 2b/3 Study of TD-1473 for Ulcerative Colitis
Theravance Biopharma announced that the first patient has been dosed in a Phase 2b/3 study to test the efficacy and safety of its candidate oral drug TD-1473 for the treatment of moderate to severe active ulcerative colitis. The Phase 2b/3 clinical trial (NCT03758443) is still recruiting participants. TD-1473 is a novel oral drug that selectively inhibits the Janus kinase (JAK) family of enzymes. The drug blocks JAK signaling pathways involved in the spread of inflammatory signals, namely those triggered by immune messengers, referred to as cytokines. Contrary to other JAK inhibitors approved for IBD and other illnesses, TD-1473 was designed to act predominantly in the gastrointestinal tract, thus overcoming potential side effects due to a generalized, or systemic, exposure to the drug. An
Subscribe or to access all post and page content.